Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$119K Sell
951
-47
-5% -$5.5K 0.02% 98
2026
Q1
$120K Buy
998
+6
+0.6% +$693 0.02% 94
2025
Q4
$110K Sell
992
-932
-48% -$87.5K 0.02% 102
2025
Q3
$179K Sell
1,924
-110
-5% -$9.06K 0.04% 84
2025
Q2
$170K Sell
2,034
-284
-12% -$22.6K 0.03% 88
2025
Q1
$184K Sell
2,318
-574
-20% -$53.6K 0.05% 76
2024
Q4
$287K Buy
2,892
+88
+3% +$9.07K 0.07% 62
2024
Q3
$310K Sell
2,804
-94
-3% -$11.2K 0.07% 61
2024
Q2
$365K Sell
2,898
-938
-24% -$121K 0.09% 53
2024
Q1
$502K Buy
3,836
+23
+0.6% +$2.83K 0.14% 45
2023
Q4
$452K Sell
3,813
-105
-3% -$10.9K 0.14% 43
2023
Q3
$407K Buy
3,918
+44
+1% +$4.74K 0.15% 47
2023
Q2
$443K Buy
3,874
+14
+0.4% +$1.59K 0.18% 50
2023
Q1
$411K Buy
3,860
+154
+4% +$16.6K 0.18% 55
2022
Q4
$411K Hold
3,706
0.2% 47
2022
Q3
$337K Buy
3,706
+159
+4% +$14.2K 0.21% 52
2022
Q2
$323K Buy
3,547
+117
+3% +$10.4K 0.22% 48
2022
Q1
$267K Hold
3,430
0.17% 62
2021
Q4
$267K Buy
3,430
+17
+0.5% +$1.35K 0.17% 62
2021
Q3
$286K Buy
+3,413
New +$260K 0.17% 61
2020
Q4
$255K Buy
+3,523
New +$269K 0.2% 60

Other funds holding MRK

Kozak & Associates's MRK Position: Q2 2026 in Review

Kozak & Associates reduced its Merck (MRK) stake by 4.7% in Q2 2026, selling an estimated $5.5K and leaving 951 shares worth $119K. The position accounts for 0.02% of the portfolio, ranked #98.

Kozak & Associates first reported a position in MRK in Q4 2020 and has held it in 21 quarters since. The position peaked at $502K in Q1 2024. 1,549 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Kozak & Associates held 951 shares of Merck worth $119K as of Q2 2026.
  • Kozak & Associates sold 47 Merck shares in Q2 2026, an estimated $5.5K.
  • Merck made up 0.02% of Kozak & Associates's portfolio in Q2 2026, its #98 holding.
  • Kozak & Associates first reported a position in Merck in Q4 2020 and has held it in 21 quarters since.
  • Kozak & Associates's Merck position peaked at $502K in Q1 2024.
  • 1,549 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Kozak & Associates's 13F filing for Q2 2026, filed 2 Jul 2026.